Ian Waxman, Development Head for Thoracic Cancers and Essential Brands at Pfizer, shared a post on LinkedIn:
“Fifteen years ago, I began drafting the first Phase 3 protocol for nivolumab—not fully anticipating the exhilarating journey that would lie ahead.
With gratitude to the remarkable mentors and friends at BMS who have guided me throughout the years, I’m excited to announce that I’ve joined Pfizer as Development Head for Thoracic Cancers and Essential Brands.
Proud to join an inspiring team of newly appointed oncology leaders Dushen Chetty Gideon Blumenthal Rod Humerickhouse Rodrigo Garcia, partnering with Johanna Bendell and Jeff Legos to achieve the next cancer breakthrough!”